Dodgers reliever Evan Phillips to undergo Tommy John surgery and miss rest of the season
Los Angeles Dodgers reliever Evan Phillips will have Tommy John surgery next week and miss the rest of the season in the latest blow to the World Series champion's pitching staff.
"Evan tried to play catch a couple days ago when we were on the road and it didn't go well, so he's going to get Tommy John surgery on the 4th," manager Dave Roberts said Friday. "Unfortunately that's going to be season-ending."
The 30-year-old right-hander had been out the last three weeks because of forearm discomfort. He didn't progress in his recovery despite what had been anticipated to be a short stint on the injured list.
"It's surprising, more disappointed for Evan," Roberts said, "but he just wasn't responding to the rest and then tried to ramp back up and so ultimately, that was kind of the advice."
Phillips began the season on the IL while recovering from a partially torn rotator cuff he sustained in the playoffs last year.
He returned in late April and made seven scoreless appearances before getting hurt during the Dodgers' trip to Miami earlier in May.
The Dodgers' staff has been riddled by injuries this season. Starters Blake Snell (shoulder inflammation), Tyler Glasnow (shoulder inflammation) and Japanese phenom Roki Sasaki (shoulder impingement) are on the IL.
Shohei Ohtani is at least 1 1/2 months away from pitching in a game while rehabbing from 2023 surgery. He's expected to face hitters for the second time this weekend.
Relievers Blake Treinen (forearm tightness) and Michael Kopech (shoulder impingement) are sidelined.
Phillips was 5-1 with a 3.62 ERA and 63 strikeouts in 54 2/3 innings last season. He is 15-9 with a 2.28 ERA in 194 games since coming to the Dodgers five years ago.
He previously played for Atlanta, Baltimore and Tampa Bay.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
29 minutes ago
- Medscape
Fewer ECG Abnormalities in Early T2D With Combo Therapy
TOPLINE: In patients with type 2 diabetes (T2D) of less than 10 years' duration who were taking metformin monotherapy, ECG abnormalities — including evidence of cardiovascular autonomic neuropathy — were common and associated with cardiovascular risk factors. After adding one of four frequently used glucose-lowering agents to metformin, fewer major ECG changes occurred with liraglutide than with the other treatments. METHODOLOGY: Researchers aimed to examine ECG abnormalities and cardiovascular autonomic neuropathy across the different glucose-lowering treatment groups in 5029 participants (mean age, 57.2 years; diabetes duration, 4.2 years; A1c level, 7.5%; 36.4% women) from the GRADE trial. The participants had T2D for less than 10 years and were initially taking metformin monotherapy before being randomly assigned to receive metformin plus one of four commonly used glucose-lowering agents (insulin glargine, glimepiride, liraglutide, or sitagliptin). Patients were followed up for an average of 5 years. Resting ECGs were recorded at baseline and at 2‐ and 4‐year follow-ups and analyzed for overall, major, and minor abnormalities, as well as heart rate variability — a measure of cardiovascular autonomic neuropathy. TAKEAWAY: More than half of participants in the GRADE trial had ECG abnormalities (57.1%) and ECG-defined cardiovascular autonomic neuropathy (52.8%) at baseline. The presence of these abnormalities was associated with longer diabetes duration, higher systolic blood pressure, greater prevalence of hyperlipidemia, more frequent use of lipid-lowering treatment, and beta-blocker use. Major ECG abnormalities occurred less frequently in the liraglutide group than in the other treatment groups (9% vs 13% at 4 years). Researchers found no significant differences in ECG-defined cardiovascular autonomic neuropathy between the liraglutide and non-liraglutide groups at 2 and 4 years (P = .42). IN PRACTICE: "ECG abnormalities, including those of CAN [cardiovascular autonomic neuropathy], are common in T2D < 10 years and are associated with certain CV [cardiovascular] risk factors. The development of major ECG abnormalities may differ by glucose-lowering treatment, as fewer occurred with liraglutide vs the other treatments," the authors concluded. SOURCE: The study was led by Rodica Pop-Busui, MD, PhD, Oregon Health & Science University in Portland. The results were presented on June 20 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center in Chicago, Illinois. LIMITATIONS: This abstract did not discuss any limitations. DISCLOSURES: Some authors disclosed receiving research support, consulting fees; serving on boards, advisory panels; being stock/shareholders; or other relationships with pharmaceutical and diagnostics companies and institutions. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
29 minutes ago
- Yahoo
Houston Rockets have second-best NBA title odds at sportsbooks after Kevin Durant trade
Before Game 7 of this year's NBA Finals tipped off, the NBA world was stunned by a Kevin Durant blockbuster deal, sending him to the Houston Rockets for Jalen Green, Dillon Brooks, the No. 10 pick in next week's 2025 NBA draft and five second-round picks. It also sent a shockwave through the odds board at sportsbooks, as the Rockets moved from the 12-1 range to around +750 to win the 2025-26 NBA championship. Those are the consensus second-best odds behind the Oklahoma City Thunder, who are well ahead of any other team at +230. Advertisement "Good trade for Phoenix, adding Jalen Green and the 10th pick is the right direction," Jeff Sherman, vice president of risk at the Westgate Las Vegas SuperBook told Yahoo Sports via text message. "We lowered Houston from 12-1 to +900 just based on perception. They should be in the mix no doubt, I just like the return for Phoenix better than what the Rockets got in a 37-year-old they have to extend." The New York Knicks (+900), Indiana Pacers (+950) and Cleveland Cavaliers (11-1) had the next-best consensus title odds at sportsbooks. "Having someone who can score in the half court was exactly what Houston was lacking all season, and it cost them dearly in the playoffs," Thomas Gable, sportsbook director at The Borgata in Atlantic City (a BetMGM book) told Yahoo Sports via text. "While this will be Durant's 18th season, he can still generate offense in the half court, even if he doesn't get to the basket as much as he used to. He should help a very young Rockets team, even if it's only a short stint." Advertisement Sherman and other oddsmakers did have Houston as the second-best team in the West in their power ratings, but cautioned the ranking was simply as of today's trade, noting, for example, if San Antonio traded for Giannis Antetokounmpo that could vault them to No. 2. "We slightly lowered the Rockets' title odds," Jeff Benson, director of sportsbook operations at Circa Sports said via direct message on X. "They upgraded and didn't give up a ton, especially the good young guys." The +750 odds are the best for the Rockets since the 2019 season, per Sports Odds History, when Houston was +700.
Washington Post
31 minutes ago
- Washington Post
Chisholm rallies Yankees to 4-2 win as New York takes 2 of 3 from Orioles
NEW YORK — Jazz Chisholm Jr. hit a go-ahead, two-run double off the right-center field wall in a three-run eighth inning, leading the New York Yankees over the Baltimore Orioles 4-2 Sunday. New York won its second straight after losing seven of its previous eight games. A day after the Orioles were held hitless for seven innings by Clarke Schmidt, Jackson Holliday singled on Will Warren's first pitch, setting up a two-run first that included Ryan O'Hearn's run-scoring single and Colton Cowser's RBI double.
